PCM
BNTX icon

Prelude Capital Management’s BioNTech BNTX Stock Holding History

Prelude Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,645
Closed -$1.26M – 1240
2024
Q3 		$1.26M Buy
+10,645
New +$979K 0.08% 321
2022
Q3 		– Sell
-3,525
Closed -$526K – 1593
2022
Q2 		$526K Sell
3,525
-100
-3% -$15.3K 0.02% 785
2022
Q1 		$618K Sell
3,625
-3
-0.1% -$504 0.02% 759
2021
Q4 		$935K Sell
3,628
-4
-0.1% -$1.1K 0.02% 649
2021
Q3 		$991K Sell
3,632
-1,118
-24% -$355K 0.03% 583
2021
Q2 		$1.06M Buy
4,750
+1,400
+42% +$264K 0.03% 581
2021
Q1 		$366K Sell
3,350
-800
-19% -$85K 0.01% 1042
2020
Q4 		$338K Hold
4,150
– – 0.01% 864
2020
Q3 		$287K Buy
4,150
+2,317
+126% +$166K 0.01% 573
2020
Q2 		$122K Buy
+1,833
New +$91.5K 0.01% 884

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Prelude Capital Management's BNTX Position: Q4 2024 in Review

Prelude Capital Management sold out of BioNTech (BNTX) in Q4 2024, closing a stake of 10,645 shares — an estimated $1.26M sold.

Prelude Capital Management first reported a position in BNTX in Q2 2020 and held it in 10 quarters. The position peaked at $1.26M in Q3 2024. 303 funds tracked by Wall St. Rank hold BNTX as of Q4 2024.

  • Prelude Capital Management reported no remaining BioNTech position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 10,645 BioNTech shares in Q4 2024, an estimated $1.26M.
  • Prelude Capital Management first reported a position in BioNTech in Q2 2020 and held it in 10 quarters.
  • Prelude Capital Management's BioNTech position peaked at $1.26M in Q3 2024.
  • 303 funds tracked by Wall St. Rank held BioNTech as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.